Ask about this productRelated genes to: CYP2B6 Blocking Peptide
- Gene:
- CYP2B6 NIH gene
- Name:
- cytochrome P450 family 2 subfamily B member 6
- Previous symbol:
- CYP2B
- Synonyms:
- CPB6, CYPIIB6
- Chromosome:
- 19q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1995-12-13
- Date modifiied:
- 2019-04-23
Related products to: CYP2B6 Blocking Peptide
Related articles to: CYP2B6 Blocking Peptide
- Interindividual variability in sertraline exposure is substantial and may be influenced by genetic variation in drug-metabolizing enzymes as well as by concomitant medications that modify enzyme activity. This study explored the association between genetic variability in the cytochrome P450 isoforms CYP2B6, CYP2C19, and CYP2D6 and sertraline pharmacokinetics in a real-world clinical setting, accounting for medication-related phenotype modification. We conducted an observational case-series analysis including seven hospitalized patients with available pharmacogenetic data and sixteen therapeutic drug monitoring measurements of sertraline. Pharmacokinetic parameters were descriptively compared across genotype-predicted metabolic phenotypes and after adjustment for concomitant medications with potential inhibitory or inducing effects, as informed by available interaction data. Before accounting for medication-related phenotype modification within a descriptive framework, variability in sertraline exposure appeared to follow patterns consistent with genotype-predicted phenotypes related to CYP2B6, whereas limited or inconsistent patterns were observed for CYP2C19 and CYP2D6. After incorporating co-medication effects, patterns across sertraline serum concentrations, concentration-to-dose ratios, and apparent clearance were more consistent for adjusted CYP2B6 phenotypes. Adjusted CYP2C19 phenotypes showed additional variability patterns in dose-normalized exposure and clearance, while no consistent associations were observed for CYP2D6 after adjustment. The metabolite-to-parent compound ratio showed no clear relationship with either genetic or adjusted phenotypes. These findings suggest that interpretation of pharmacogenetic information for sertraline may benefit from integrating CYP2B6 and CYP2C19 genotype data with concomitant medication use. In this exploratory case series, accounting for medication-related phenotype modification revealed variability patterns that were less evident when genetic information was considered alone. Current guidelines consider CYP2B6 and CYP2C19 actionable for sertraline; our findings suggest that integrating co-medication-informed interpretation with pharmacogenetic testing and therapeutic drug monitoring may further refine individualized assessment of sertraline exposure in complex clinical settings. - Source: PubMed
Publication date: 2026/06/10
Tapia-Alzuguren BegoñaCanga-Espina CovadongaMolero PatricioAldaz Azucena - (200/200 words)Resmetirom is a liver-directed, thyroid hormone receptor-β (THR-β)-selective agonist approved for treatment of adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced liver fibrosis. Disposition in rats and dogs was qualitatively similar to that observed in humans, with high concentrations observed in liver, kidney, and cecum. The primary circulating metabolite, MGL-3623 (M1), was disproportionate in humans and formed predominantly via CYP2C8. Resmetirom exhibited >99% plasma protein binding in all species and was a substrate for BCRP, OSTα/β, OATP1B1/B3, and, to a lesser extent, MDR1.A [C]resmetirom mass balance study in healthy men pre-dosed with 100 mg/d resmetirom (steady-state) demonstrated plasma pharmacokinetics of total radioactivity aligned with unlabelled resmetirom and MGL-3623, with C reached within 3-4 h. Radioactivity was largely confined to plasma vs whole blood, with parent compound the predominant radiolabelled species and MGL-3623 the major metabolite. Total recovery was 91.0% (excretion: 67.4% faecal, 23.6% urinary); in excreta, resmetirom was a minor component and no single metabolite exceeded 10% of dose. Resmetirom inhibited CYP2C8 and weakly induced CYP2B6 and CYP3A4 in vitro.These findings demonstrate the consistent metabolic profile and favourable hepatic disposition of resmetirom across species, supporting its pharmacokinetic properties in humans for treatment of MASH. - Source: PubMed
Publication date: 2026/06/09
Hennan James KCamacho Raul CSolon EricSchmidt BrianFrench KevinChiang EdwardTaub Rebecca - Although changes in the lung microbiome have been observed in many respiratory diseases, the lung microbiome of patients with tuberculosis (TB) remains largely undefined. The aim of this study was to determine and compare the composition of upper and lower respiratory microbial communities, changes in host gene expression, and functional pathway activation in patients with TB and community-acquired pneumonia using a Metatranscriptomic approach. - Source: PubMed
Publication date: 2026/06/06
Li LiangyuXu MengLiu MenglingMao JieyuXiong PeiLi RuiyunChen JianjunWu Xiaojun - IntroductionDrug metabolism is primarily carried out by the cytochrome P450 (CYP) family of enzymes in the liver. Based on an individual's diplotype, they can be classified into poor (PM), intermediate (IM), normal (NM), rapid (RM) or ultrarapid (UM) metabolizers. Here, we show the distribution of allele frequency and metabolizer status across ancestries for and in a cohort from Ontario, Canada.MethodsPatients currently taking or starting a psychotropic drug ( = 8,280) were enrolled. Patients self-reported their ancestry, and DNA was analysed for the and genes using a commercial pharmacogenetic test and metabolizer status was assigned using ClinPGx as a reference.ResultsThe cohort was primarily of European ancestry (70%), followed by individuals with mixed ancestry (9.3%). The combined frequency of PMs and UMs, representing the extremes of enzyme activity, was highest for CYP2C19 and CYP2D6, with this frequency being approximately 8% for each enzyme. The frequency varied considerably by ancestry, with up to 24% of individuals of Caribbean descent being CYP2C19 PMs or UMs, for example, compared to only 7% among those of Latin, Central and South American ancestry. Of the entire sample, only 5.1% were NMs across all enzymes, meaning 94.9% of individuals had a non-NM status and would benefit from pharmacogenetic testing.ConclusionOverall, this study provides a useful reference for variations in the family of genes in the population of Ontario, Canada. - Source: PubMed
Publication date: 2026/06/04
Thamilselvan MeganaCoulter Alex JHerbert DeannaShahmirian AnasheKing NicoleMüller Daniel JTiwari Arun KumarZai Clement CKennedy James L - Systemic exposure of a sensitive probe is considered a 'gold standard' for assessment of clinical relevance of a potential cytochrome P450 (CYP)-driven drug-drug interaction (DDI). Typically, the change in systemic exposure is judged by the area under the concentration-time curve [AUC]) of the parent, but sometimes metabolite exposure is used to further elucidate the mechanism of the DDI. - Source: PubMed
Publication date: 2026/06/03
Dubich Tatyanavan Iersel ThijsMirdamadi Kameliavan Hoogdalem Ewoud-Jan